Immune Checkpoint Blockade (ICB) Data

The development of immune checkpoint blockade (ICB) has changed the way we
treat various cancers and led to the development of several new compounds that
are now under clinical investigation. Despite the large number of Immune
checkpoint inhibitors (ICB) clinical trials with available molecular data
published every year, it is still complicated to assess the reproducibility of
immune-oncology (IO) predictive and prognostic biomarkers. Recently, multiple
biomarkers have been reported to be associated with immunotherapy response,
however tumor complexity and heterogeneity limit the use of research context
biomarkers in clinical practice. We have recently performed a meta-analysis of
public clinical genomic datasets of patients treated with immunotherapies to
assess the predictive value of published biomarkers and mRNA signatures. The
collection of datasets contain a broad number of ICB clinical trials, with
both molecular and clinical data available.